Risk of Infections and Cancer in Patients With Rheumatologic Diseases Receiving Interleukin Inhibitors: A Systematic Review and Meta-analysis

IMPORTANCE: The safety profile of interleukin (IL) inhibitors is not well established. OBJECTIVE: To assess the risk of serious infections, opportunistic infections, and cancer in patients with rheumatologic diseases treated with IL inhibitors. DATA SOURCES: Ovid MEDLINE and Epub Ahead of Print, In-...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilal, Jawad, Berlinberg, Adam, Riaz, Irbaz Bin, Faridi, Warda, Bhattacharjee, Sandipan, Ortega, Gilbert, Murad, Mohammad H., Wang, Zhen, Prokop, Larry J., Alhifany, Abdullah A., Kwoh, C. Kent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2019
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813598/
https://www.ncbi.nlm.nih.gov/pubmed/31626313
http://dx.doi.org/10.1001/jamanetworkopen.2019.13102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6813598/
https://www.ncbi.nlm.nih.gov/pubmed/31626313
http://dx.doi.org/10.1001/jamanetworkopen.2019.13102

Ejemplares similares